Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
16.78
+0.85 (+5.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
35
36
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 24, 2024
Via
Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
↗
May 23, 2024
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy.
Via
InvestorPlace
Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir
↗
May 22, 2024
Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs...
Via
Benzinga
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
↗
May 20, 2024
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.
Via
Investor's Business Daily
12 Analysts Have This To Say About Sarepta Therapeutics
↗
May 20, 2024
Via
Benzinga
What Analysts Are Saying About Sarepta Therapeutics Stock
↗
May 02, 2024
Via
Benzinga
Sarepta Therapeutics: Q4 Earnings Insights
↗
February 28, 2024
Via
Benzinga
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
↗
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
May 03, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
↗
May 02, 2024
Via
Benzinga
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 01, 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
↗
May 01, 2024
SRPT earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
May 01, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
1 Top Growth Stock to Buy and Hold for 10 Years
↗
May 01, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Stock Shows Improved Technical Strength
↗
April 29, 2024
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.
Via
Investor's Business Daily
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
↗
April 08, 2024
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.
Via
Investor's Business Daily
2 Biotech Stocks to Buy Hand Over Fist in April
↗
April 06, 2024
These drugmakers have made important moves over the past year.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
April 04, 2024
Via
Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
↗
March 28, 2024
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.
Via
Investor's Business Daily
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
↗
March 13, 2024
The threat is still emerging, but it could be significant.
Via
The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
↗
March 08, 2024
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.
Via
Benzinga
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
↗
March 08, 2024
These stocks haven't been able to get much traction lately, even though they clearly deserve to now.
Via
The Motley Fool
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
↗
March 04, 2024
The upcoming regulatory decision on its latest drug could be big.
Via
The Motley Fool
Sarepta Therapeutics to Present at Upcoming Investor Conferences
March 04, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
↗
February 29, 2024
SRPT earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
